# A Phase I/IIa Study of Cerebraca Wafer Plus Adjuvant Temozolomide (TMZ) in Patients With Recurrent High Grade Glioma

> **NCT03234595** · PHASE1,PHASE2 · COMPLETED · sponsor: **Everfront Biotech Co., Ltd.** · enrollment: 22 (actual)

## Conditions studied

- Recurrent GBM

## Interventions

- **DRUG:** Cerebraca wafer

## Key facts

- **NCT ID:** NCT03234595
- **Lead sponsor:** Everfront Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-01
- **Primary completion:** 2023-04-30
- **Final completion:** 2024-09-03
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2024-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03234595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03234595, "A Phase I/IIa Study of Cerebraca Wafer Plus Adjuvant Temozolomide (TMZ) in Patients With Recurrent High Grade Glioma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03234595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*